Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$46.1K Hold
499
﹤0.01% 454
2022
Q3
$40K Sell
499
-10
-2% -$945 ﹤0.01% 453
2022
Q2
$50K Sell
509
-170
-25% -$17.9K ﹤0.01% 417
2022
Q1
$81K Sell
679
-73
-10% -$8.78K 0.01% 366
2021
Q4
$102K Sell
752
-9
-1% -$1.3K 0.01% 330
2021
Q3
$118K Sell
761
-1,567
-67% -$255K 0.01% 311
2021
Q2
$337K Buy
2,328
+288
+14% +$40.4K 0.03% 202
2021
Q1
$269K Buy
2,040
+412
+25% +$51.3K 0.02% 214
2020
Q4
$195K Buy
1,628
+233
+17% +$25.8K 0.02% 246
2020
Q3
$132K Buy
1,395
+169
+14% +$16.9K 0.01% 257
2020
Q2
$120K Sell
1,226
-133
-10% -$11.4K 0.01% 250
2020
Q1
$102K Buy
1,359
+6
+0.4% +$543 0.01% 251
2019
Q4
$132K Buy
1,353
+101
+8% +$9.42K 0.01% 247
2019
Q3
$106K Sell
1,252
-94
-7% -$7.58K 0.01% 253
2019
Q2
$107K Sell
1,346
-195
-13% -$16K 0.01% 273
2019
Q1
$133K Buy
1,541
+130
+9% +$9.79K 0.02% 249
2018
Q4
$89K Buy
1,411
+76
+6% +$4.92K 0.01% 287
2018
Q3
$94K Buy
1,335
+813
+156% +$53.3K 0.01% 287
2018
Q2
$32K Buy
+522
New +$31.3K ﹤0.01% 426

Other funds holding GRMN

Sargent Bickham Lagudis's GRMN Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Garmin (GRMN) position steady in Q4 2022 at 499 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

Sargent Bickham Lagudis first reported a position in GRMN in Q2 2018 and has held it in 19 quarters since. The position peaked at $337K in Q2 2021. 630 funds tracked by Wall St. Rank hold GRMN as of Q4 2022.

  • Sargent Bickham Lagudis held 499 shares of Garmin worth $46.1K as of Q4 2022.
  • Sargent Bickham Lagudis left its Garmin share count unchanged in Q4 2022.
  • Garmin made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #454 holding.
  • Sargent Bickham Lagudis first reported a position in Garmin in Q2 2018 and has held it in 19 quarters since.
  • Sargent Bickham Lagudis's Garmin position peaked at $337K in Q2 2021.
  • 630 funds tracked by Wall St. Rank held Garmin as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.